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 7 
Abstract 8 
The performance of a biomass adapted to Oncological Ward Wastewater (OWW) in a 9 
membrane bioreactor (MBR) was compared with that of a municipal WWTP, on the 10 
removal of pharmaceutical molecules and more specifically on their overall resistance 11 
and purifying ability in the presence of pharmaceutical cocktails. Sorption and 12 
biotransformation mechanisms on two antineoplastics, one antibiotic and a painkiller 13 
were evaluated. Sludge acclimated to OWW allowed for a 34% increase in the removal 14 
rate and in the minimum inhibition concentration. The percentage of the amounts of 15 
specific pharmaceutical compounds removed by biotransformation or by sorption were 16 
measured. These results are positive, as they show that the observed removal of 17 
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pharmaceutical molecules by biomass acclimated to OWW can mostly be attributed to 18 
developed biotransformation, unlike the biomass from the municipal WWTP for which 19 
sorption is sometimes the only removal mechanism. The biotransformation kinetic and 20 
the solid-water distribution coefficients in this study show good agreement with 21 
literature data, even for much higher pharmaceutical concentrations in OWW. 22 
 23 
Keywords 24 
Pharmaceutical compounds; Acclimated sludge; pharmaceutical removal; sorption; 25 
biotransformation  26 
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I. Introduction 27 
The removal of pharmaceutical residues in wastewater treatment plants (WWTP) by 28 
activated sludge is carried out through two mechanisms: biotransformation (biological 29 
removal and metabolization of the parent molecule) and sorption; photo transformation 30 
and air-stripping are negligible (POSEIDON 2006). The biotransformation of 31 
pharmaceutical compounds follows a pseudo-first order model (Joss et al., 2006) in a 32 
concentration range which does not inhibit biomass. The Hydraulic Retention Time 33 
(HRT) may therefore be optimized according to concentrations at process input and to 34 
the value of the ki,biol constant of the pharmaceutical molecule. So the ki,biol constant 35 
depends on the degradability of the compound but also on the composition of the sludge, 36 
which influences the mechanism of biodegradation of pharmaceutical compounds in 37 
several ways. Joss et al. (2006) classified pharmaceutical compounds into 3 groups, 38 
according to their constants (i) ki,biol < 0,1 L.gTSS-1.d-1 : no significant 39 
transformation/removal through biodegradation; (ii) 0,1 < ki,biol < 10 L.gTSS-1.d-1 : 40 
partial removal (20 % to 90 %) and (iii) ki,biol > 10 L.gTSS-1.d-1 : more than 90% 41 
transformation/removal via biodegradation. Their results show that only 4 out of the 35 42 
pharmaceuticals molecules studied (estrone, estradiol, ibuprofen and paracetamol) 43 
could be removed by 90% through biotransformation but that this mechanism could be 44 
overestimated for a third of the compounds studied. It does not seem possible to 45 
conclude on the bio transformability of a pharmaceutical molecule because of the few 46 
exceptions that were obtained for antibiotics and anti-inflammatory agents. So the ki,biol 47 
constant must be determined experimentally. pH, redox potential, stereochemical 48 
structure and the chemical structure of the sorbent and of the sorbed molecule may 49 
influence the effect of the sorption mechanism on the activated sludge (Kümmerer, 50 
2009), be it through adsorption or absorption. Thus the influence of pH on the removal 51 
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of ionizable micropollutants in a Membrane Bioreactor (MBR) was confirmed by 52 
applying an acid pH which modified the hydrophobicity of some compounds which are 53 
not inclined to sorption on the bacterial flocs at a neutral pH (Urase et al., 2005; 54 
Tadkaew et al., 2010). The solid-water partition coefficient	, also called Nernst 55 
coefficient, was then introduced as the most appropriated parameter representing the 56 
sorbed fraction of a molecule on suspended matter (Schwarzenbach et al., 2003; Ternes 57 
et al., 2004). The sorption of a compound is considered negligible for municipal WWTP if 58 
 is smaller than 500 L.kgTSS-1 as it would represent less than 10% removal (Ternes et 59 
al., 2004). Joss et al. (2005) give a lower threshold value at 300 L.kgTSS-1, before taking 60 
the sorption mechanism into account. Sipma et al. (2010) conclude that the sorption of 61 
pharmaceutical compounds on activated sludge is generally a minor removal 62 
mechanism, due to the low values of  in pharmaceuticals. Numerous pharmaceutical 63 
molecules are hydrophilic, which a priori limits sorption phenomena. Nevertheless, very 64 
hydrophilic molecules, such as antibiotics from the fluoroquinolone class, are removed 65 
very efficiently through sorption due to electrostatic interactions (Göbel et al., 2007; 66 
Vieno et al., 2007). Out of 40 micropollutants that were studied in an MBR, the 14 very 67 
hydrophobic molecules were all removed at more than 85% (Tadkaew et al., 2011). It is 68 
necessary to distinguish between the 2 mechanisms of pharmaceutical micropollutants 69 
removal in order to estimate the proportion transferred to the sludge, which would 70 
allow for an assessment of the environmental relevance of the removal procedure / 71 
disposal of excess WWTP sludge.  72 
Moreover, the treatment process may influence the ability of the biomass to resist toxic 73 
charges, as Henriques et al. (2005-2007) state that some processes are more sensitive to 74 
inhibition: it is the case of activated sludge flocs, which boost the formation of small 75 
aggregates (such as MBR) and processes involving a high shear. In their study, 76 
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respirometric tests on the biomasses of 2 MBR revealed an inhibition 1.25 and two times 77 
greater than that of a conventional activated sludge process while in contact with 78 
chemical toxins, with MBR bacterial flocs smaller by 41%.  79 
The choice of treatment process configuration is very important in its ability to resist the 80 
presence of toxic material, as shear stress rate is different according to configuration. It 81 
is therefore expected that the MBR configuration may influence the ability of activated 82 
sludge to resist and to acclimate to a highly concentrated pharmaceuticals effluent. For 83 
this study, we decided to compare the performance of a biomass adapted to Oncological 84 
Ward Wastewater (OWW) with that of a municipal WWTP, on the removal of 85 
pharmaceutical molecules and more specifically on their overall resistance to the 86 
presence of pharmaceutical cocktails and the preservation of their purifying ability. 87 
Removal of one of the oncological ward’s most consumed antineoplastics (5-FU) was 88 
quantified for both biomasses. Then removal of easily biodegradable substrate in the 89 
presence of pharmaceutical cocktails (antineoplastics and antibiotics) was measured for 90 
both biomasses in order to determine whether (i) adaptation to OWW permitted to 91 
increase resistance of the biomass to pharmaceuticals and whether (ii) one class of 92 
pharmaceuticals is more harmful than another to the performance of both biomasses. 93 
This objective arose from the different uses of antineoplastics and antibiotics in 94 
hospitals. While antineoplastics and antibiotics are administered continuously in 95 
oncologic wards, the antibiotics are given to prevent possible post-surgical infections 96 
and their concentrations in effluent can be strongly modified as a function of time and 97 
the number of patients. Hence it is assumed that the adaptation of the biomass to 98 
antibiotics is made all the more delicate by the occasional presence of concentration 99 
peaks in hospital effluents (OWW). Finally sorption and biotransformation mechanisms 100 
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on two antineoplastics, one antibiotic and a painkiller were studied for both activated 101 
sludge. 102 
 103 
II. Equipment and methods 104 
II.1. MBR and hospital effluents  105 
A pilot-scale membrane bioreactor was designed, built and set up underneath the 106 
oncological ward of the Timone hospital (Marseille, France). The MBR pilot was designed 107 
for treating 1 to 2 L.h-1 of hospital effluent from the oncological ward. The pilot has a 108 
maximum capacity of 60 L, with an operating volume set at 32 L. A 3.1 kW refrigeration 109 
unit allowed for regulation of activated sludge temperature at 25 ± 2°C. OWW were kept 110 
in a storage tank with a maximum capacity of 200 L and were renewed every other day. 111 
First, OWW were sent into the denitrification tank (10.5 L) which was stirred through 112 
sludge recirculation carried out by a peristaltic pump. The dissolved oxygen 113 
concentration is continuously monitored in the denitrification reactor in order to check 114 
its zero value. The bacterial flocs were maintained in suspension without aerating the 115 
anoxic zone, which allowed the denitrification reaction to take place. A fraction of the 116 
recirculated sludge was transferred to the aerobic tank, which has a capacity of 21.5 L, 117 
and in which the nitrification reaction took place. The hydraulic retention time (HRT) in 118 
both tanks was set through the adjustment of valves, which established 1h/2h cycles in 119 
the anoxic and anaerobic tanks respectively. Aeration was performed by fine air bubbles 120 
delivered through four porous tubes connected to a compressor. This maintained 121 
oxygen concentration above 2 mg.L-1 and ensured the stirring of the aerobic tank. A 122 
centrifugal pump (B3, Motovario) located at the foot of the nitrification tank performed 123 
suction of the activated sludge towards the membrane module. Two acclimation 124 
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campaigns to OWW were carried out: one using an external membrane bioreactor 125 
(eMBR) and another using an external submerged membrane bioreactor (sMBRe). The 126 
biomasses from the eMBR and sMBRe were acclimated to effluents from the Timone 127 
oncological ward (Marseille) for more than 150 days each (Hamon, 2014). The pipe 128 
collected wastewater from 6 rooms without dilution by the ward’s other activities. 129 
Pretreatment consisted of maceration with a Saniflo (Plus Silence, SFA) and 0.5 mm cut 130 
off filtration. After a few days of operation sampling of the OWW was carried out at night 131 
in order to avoid dilution by shower drain water, thus an effluent with a higher 132 
ammonium content was obtained. In spite of the standardization of the sampling 133 
method, large fluctuations in COD and N-NH4+ concentrations were measured. COD and 134 
N-NH4+ concentrations were stabilized by feeding the MBR pilot with half OWW and half 135 
synthetic substrate during the second half of the first acclimation campaign in an eMBR 136 
configuration. Composition of the synthetic substrate which allowed for dilution of the 137 
polluting charge specific to OWW was determined using the average COD (800 mg.L-1 as 138 
sugar C6H12O6) and N-NH4+ (31 mg.L-1 as (NH4)2SO4) concentrations, which were 139 
measured over a two-month period. Concentrations in mineral salts were set according 140 
to literature (Han et al., 2005 ; Barrioz-Martinez, 2006): C/N/P ratio of the synthetic 141 
effluent was 100/4/2. In both MBR configurations the retentate was returned to the 142 
nitrification tank while the permeate was sent back to the oncological ward waste water 143 
pipe. The features of both MBR, of the acclimation parameters and of the activated 144 
sludge are listed in table 1.  145 
 146 
II.2 Compounds and analysis 147 
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The three most consumed antineoplastics in the oncological ward of the Timone hospital 148 
are among the seven antineoplastics on the French national agency of sanitary safety of 149 
food, environment and work (Anses) list: ifosfamide (IF), fluorouracil (5-FU) and 150 
cyclophosphamide (CP). Fluorouracil was analyzed by the pharmacology and 151 
toxicokinetics laboratory of the Timone hospital (Marseille, France). Ifosfamide, 152 
cyclophosphamide, codeine and sulfamethoxazole were analyzed by the Ianesco 153 
laboratory (Institut d’Analyses et d’Essais en Chimie de l’Ouest, Poitiers, France). This 154 
laboratory is COFRAC-certified to analyze the specific molecules studied in our paper. 155 
The COFRAC accreditation certifies the technical competence of testing and calibration 156 
laboratories to perform specific tasks. The procedure for dosing 5-FU in blood plasma 157 
was successfully applied to OWW and treated water. 5-FU was analyzed with HPLC-UV 158 
(254 nm). The limit of quantification was 5 µg.L-1. The detection limits were obtained 159 
with several injections of compounds from 1 to 10 µg.L-1. An accurate detection and 160 
repeatability were obtained from the concentration at 5 µg.L-1. In detail, the analytical 161 
system was divided into three parts: (A) a mobile phase composed of 0.05 M 162 
monopotassium phosphate (KH2PO4) was adjusted to pH 3 with orthophosphoric acid 163 
and filtration at 0.2μm. (B) 500μL of the sample to be analyzed was acidified with 20μL 164 
of 5% orthophosphoric acid; ibromouracil (50mL, 10μg.mL-1) was added. The sample 165 
was extracted with 6 mL of n-propanol/diethylether 10:90 (v:v), mixed with an 166 
automatic vortex for 10 minutes before centrifugation for 15 minutes at 3000 g at 4°C. 167 
The organic phase was sampled and evaporated in a water bath under nitrogen. The dry 168 
residue was recovered in 100 μL of mobile phase and was centrifuged for 4 minutes. (C) 169 
The samples were analyzed by HPLC-UV: 7 solvent samples were injected for calibration 170 
(the 7 samples covered the whole concentration range), then the samples to be analyzed 171 
were injected, and finally 3 samples were injected for quality control. The four 172 
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remaining molecules (cyclophosphamide, ifosfamide, sulfamethoxazole and codeine) 173 
were analyzed simultaneously by liquid chromatography combined with tandem mass 174 
spectrometry (LC/MS-MS). Detection limits were first estimated by calculation by 175 
injecting a low-concentration standard solution: the limit of detection is at least equal to 176 
3 times the background noise and the limit of quantification is, to a minimum, equal to 177 
10 times the signal of the background noise. The quantification limits were controlled by 178 
injecting a standard solution at this given concentration. Then real samples were doped 179 
at this given concentration in order to assess the accuracy and reliability of the 180 
analytical method. The limit of quantification of the method was 2.5 µg.L-1. The LC/MS-181 
MS was calibrated with a 200mg.L-1 solution of our molecules of interest in methanol. A 182 
calibration range of 0, 1, 2.5, 10, 30, 50 and 100 µg.L-1 in ultrapure water / methanol 183 
(80/20) was obtained by diluting the deuterated internal standards to 30 µg.L-1 184 
(sulfamethoxazole-D4, diclofenac-D4, ketoprofenD4 and caffeine). In detail, the 185 
analytical system used was composed of an AGILENT 1100 HPLC equipped with a high 186 
pressure pump, an automatic injector (thermostated by Peltier effect) and a SCIEX, 187 
API400 tandem mass spectrometer. Quantification was carried out with a calibration in 188 
solutions containing internal standards. The analytical conditions were: (i) an analytical 189 
column: ZORBAX Eclipse Plus C18 (100mm x 2.1mm x 3.5μm) with guard pre-column 190 
ZORBAX Eclipse Plus C18 (5 μm x 12.5 mm). (ii) The solvent gradient parameters were 191 
set through two channels: channel A: ultra-pure water with 0.1% formic acid and 192 
channel B: methanol, with a flow rate of 0.35 mL.min-1. The solvent gradient was 193 
modified at 0-4/12/16/20/24/25/40 min with the respective ratios (A-B) 95-5/70-194 
30/30-70/2-98/1-99/0-100/95-5/95-5%. The injected volume was 20 μL and the oven 195 
temperature was 25°C. The electrospray ionization mode (positive-mode Turbo-V) was 196 
positive mode (ion formation [M+H]+ mostly but also potentially Na+ or K+ adducts). The 197 
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de-solvation temperature, the acquisition mode, the duration of the MRM windows and 198 
the duration of analysis were respectively 550°C, MRM, 200s and 44 minutes. The 199 
retention times for codeine, sulfamethoxazole, ifosfamide and cyclophosphamide were 200 
respectively 5.4/8.5/10.5/11 min. Prior to analysis, wastewater was decanted then 201 
filtered on a 0.45 µm porosity filter. Removal of the coarsest solid materials should not 202 
lead to under-estimating the pharmaceutical concentration in OWW, as the selected 203 
pharmaceuticals are excreted solely through the urinary tract and are hydrophilic. Thus 204 
sorption on TSS of OWW is negligible. The analytical LOQ might seem high regarding 205 
pharmaceutical concentration in municipal wastewater but is satisfying regarding the 206 
oncological ward wastewater which was investigated. 207 
 208 
II.3 Pharmaceutical cocktails  209 
The influence of various pharmaceutical cocktails on the performance of both biomasses 210 
(acclimated to OWW and municipal WWTP) was assessed by using the kinetics of 211 
degradation of easily degradable substrates (COD, NH4+) in a batch reactor. The 212 
pharmaceutical cocktails were prepared using hospital pharmaceuticals. The 213 
composition of the antineoplastics cocktail was based on the maximum concentration of 214 
5-FU found in OWW during the acclimation period of the biomass, i.e. 1287 µg.L-1, on the 215 
metabolization rate of each pharmaceutical and on the maximum quantity consumed in 216 
the oncological ward unit to which the MBR was connected. The concentrations thus 217 
calculated are shown in Table 2. 218 
ℎ	

 = 5 −  ∙
 !"#$ %
&'()
∙ *+, !"#$ %*+,&'()  Eq. 1 219 
 220 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
with:  221 
5 − : Maximum concentration in 5-FU detected in OWW during the first 222 
experimental campaign (µg.L-1) 223 
npharmaceutical: annual consumption of the pharmaceutical in the unit (mg.year-1) 224 
n5-FU: annual 5-FU consumption in the unit (mg.year-1) 225 
1-τpharmaceutical: non-metabolized pharmaceutical rate (-) 226 
1-τ5-FU: non-metabolized 5-FU rate (-) 227 
 228 
The concentrations of the antibiotics cocktail were defined arbitrarily in order to obtain 229 
a total concentration in the same order of magnitude as that of the antineoplastics. Thus 230 
the concentration of each of the ward’s four most consumed antibiotics was set at 1 231 
mg.L-1 (Table 2). 232 
It should be noted that these cocktails do not in any way represent the average or the 233 
maximum concentrations that could be detected in OWW. Five original COD 234 
concentrations plotted to the quantity of TSS were tested for each “type of biomass – 235 
pharmaceutical cocktail” pair: 0.1 – 0.2 – 0.5 – 1 – 3 gCOD.gTSS-1. Total duration of the 236 
tests was 4h. However, the duration that was used to calculate the maximum 237 
degradation velocity varied according to original concentrations and corresponded to 238 
the linear degradation velocity of the COD. 239 
 240 
II.4 Sorption and biotransformation tests 241 
The technique to inhibit activated sludge must be adapted to sorption tests: it must 242 
allow for complete inhibition of the biotransformation mechanism and for preservation 243 
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of the structural integrity of the activated sludge. Prior to sorption text, it was necessary 244 
to determine the most suitable activated sludge inhibition technique for carrying out 245 
these tests in order to ensure the consistency of batch tests with sorption phenomenon 246 
in the MBR: gas purging is the only technique that does not affect the structure of the 247 
biomass (Hamon et al. 2014). Moreover, this inhibition is very easily implemented and 248 
the inhibition state is reached immediately, as the concentration in dissolved oxygen 249 
drops down almost instantaneously to zero. The quantity of the selected 250 
pharmaceuticals, which were removed thanks to the sorption mechanism was evaluated 251 
for the activated sludge from the sMBRe pilot and from the municipal WWTP of Rousset 252 
(France). The sorption tests were carried out over 4h as this duration allows ifosfamide 253 
and cyclophosphamide to reach sorption equilibrium, whatever the origin of the 254 
activated sludge (Seira, 2013). Sorption equilibrium of sulfamethoxazole was reached in 255 
2h (Yang et al., 2011). There is no available data concerning codeine. Activated sludge 256 
filtered with coffee filters (average pore size 100 µm) was re-suspended with distilled 257 
water, so as not to use the supernatant from the sMBRe pilot, as it was likely to contain 258 
the selected pharmaceuticals at considerable concentrations, which could distort results. 259 
Activated sludge concentration in TSS was brought down to 4 g.L-1 using coffee filters. 260 
Sorption tests were performed on pharmaceutical cocktails in 4 different original 261 
concentrations close to 100 – 250 – 500 and 1000 µg.L-1. The original measured 262 
concentrations were slightly different but in the correct order of magnitude. Thus, to 263 
allow for easier reading, results are presented according to that concentration factor (1 264 
– 2.5 – 5 and 10). Reductions and KD values were calculated using actual original 265 
concentrations. The activated sludge was placed in anaerobic conditions. Water was 266 
deoxygenated with dinitrogen, the pharmaceuticals were introduced and the initial 267 
sample was taken. Sorption tests were carried out in closed 200 mL brown glass vials 268 
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filled completely and slightly stirred to ensure homogeneous mixing and avoid 269 
sedimentation of sludge particles. The null value of the dissolved oxygen was checked 270 
once every hour during tests. In biotransformation tests degradation kinetics of the 271 
selected pharmaceuticals were performed in brown glass vials, aerated over 4h, with 272 
sludge acclimated to OWW and WWTP sludge. Similarly to sorption tests, activated 273 
sludge concentration in TSS was brought down to 4 g.L-1. Filtered sludge was re-274 
suspended with distilled water. The initial concentrations of the pharmaceutical 275 
cocktails were identical to that of the sorption tests, i.e. close to the targeted 276 
concentrations 100 – 250 – 500 and 1000 µg.L-1, and allowed us to respect the 277 
concentration factor 1 – 2.5 – 5 and 10. 278 
 279 
III. Results  280 
III.1. Removal Performance 281 
III.1.1. 5-FU 282 
During the acclimation phase, 5-FU was almost consistently detected in OWW at 283 
concentrations up to 1287 µg.L-1 (minimum 49.6 µg.L-1 / average 440 µg.L-1 / 150 days). 284 
These concentrations are very high compared with those measured in previous 285 
research: between 11.5 and 122 µg.L-1 for Mahnik et al. (2007) and between 35 and 92 286 
ng.L-1 for Kosjek et al. (2013). The permeate samples which were analyzed show good 287 
removal of 5-FU by acclimated activated sludge, as reductions are above 90% in spite of 288 
high initial concentrations, sometimes greater than 1 mg.L-1. Specific degradation 289 
velocity seems relatively proportional to the 5-FU initial concentration (pseudo-first 290 
order) (Figure 1). If the VspecificMBR > LOQ and VspecificMBR < LOQ, the velocity was 291 
calculated from the value of the measured concentration and from the value of the LOQ 292 
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respectively. Removal of 5-FU was assessed during similar research on treatment of 293 
OWW in an Austrian hospital using MBR (Mahnik et al., 2007). Results proved similar, 294 
with total removal of 5-FU, as 5-FU could no longer be quantified at process output. In 295 
the present study and even if the LOQ can be considered to be high, the concentrations 296 
in the effluent are so high that removal is always higher than 95%. Obviously, each 297 
removal rate is calculated from specific measured data. By using batch degradation tests 298 
with radiolabeled compounds Mahnik et al. (2007) noticed total 5-FU removal from the 299 
liquid phase and negligible sorption onto the activated sludge, ranging from 2 to 5%. 300 
Thus 5-FU is almost totally removed by biotransformation. The capacity of 5-FU to be 301 
biotransformed at low and high concentrations had already been shown by some 302 
authors (Kiffmeyer et al., 1998 ; Yu et al., 2006). However, these results were obtained 303 
by conducting tests on high concentrations which do not reflect the actual situation, as 304 
there might be an inhibitory effect and the analytical methods used were sometimes 305 
unsuitable (measurement of COD or of produced CO2). Thus Kümmerer (1997) observed 306 
contradictory results: he found no biotransformation of 5-FU for very high 5-FU 307 
concentrations (9 and 850 mg.L-1). In this present study, degradation kinetics for 5-FU 308 
were performed on sludge from the municipal WWTP and on sludge acclimated to OWW 309 
in batch reactors for 5 initial concentrations: 50 – 1000 µg.L-1. The kinetics were 310 
performed over 21h so as to match the HRT of the eMBR pilot at the time of sampling. 311 
The sludge from the municipal WWTP was adjusted to the concentration of the 312 
acclimated sludge, i.e. 4.1 g.L-1. Whatever the concentration, 5-FU reduction was always 313 
slightly greater for acclimated sludge than for sludge sampled from municipal WWTP. In 314 
that concentration range the activated sludge from municipal WWTP also seemed very 315 
efficient for the removal of 5-FU, as the minimum reduction was always greater than 316 
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80%. 5-FU reductions by both types of sludge, as well as associated specific degradation 317 
velocities are presented in Figure 2.  318 
Just as with sludge acclimated to OWW, the higher the initial concentration, the greater 319 
the reduction was, which shows that the concentration range, which was tested (50 – 320 
1000 µg.L-1) was lower than a possible inhibition threshold; the kinetics remained 321 
pseudo-first order. Acclimation to OWW allowed the biomass to be slightly more 322 
efficient at initial low concentrations (50 – 200 µg.L-1). This improvement is minor as 5-323 
FU proved to be a very easily removable molecule. Thus the specific removal velocities 324 
of 5-FU were almost the same: 0.0115 gTSS-1.h-1 for the acclimated sludge and 0.0114 gTSS-325 
1.h-1 for the municipal WWTP. However it is very important to note that in spite of the 326 
numerous pharmaceuticals, metabolites and cleaning products contained in the OWW 327 
which was used for acclimation, the acclimated biomass proved to be at least as efficient 328 
as the WWTP sludge, which only removed 5-FU during those tests. Nevertheless the 329 
kinetics study allowed for identification of a few behavioral differences in both types of 330 
sludge. The degradation kinetic constants kbiol were calculated between t=15 min and 331 
t=90 min as the term ln(C/C0) is linear in that range, thus confirming that the 332 
degradation kinetics is pseudo-first order for the first 90 minutes (Figure 3).  333 
The evolution of the degradation constant kbiol shows that acclimation at the source 334 
allows for faster removal of 5-FU. Thus an average 34% increase was reached for the 335 
acclimated sludge, compared with WWTP sludge. The variation of kbiol constants shows 336 
that WWTP reached a threshold, while the kbiol constants continue to evolve beyond 337 
1000 µg.L-1 for the acclimated sludge. Hence, it seems that the minimum inhibition 338 
concentration is lower for WWTP sludge than for sludge acclimated to OWW in the MBR.  339 
 340 
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III.1.2. Performance with pharmaceutical cocktails 341 
The influence of antineoplastics and antibiotics cocktails was quantified in the biomass 342 
acclimated to OWW and in a biomass from a municipal WWTP, by monitoring the 343 
degradation of an easily biodegradable substrate. Specific degradation velocities of the 344 
COD were calculated for each “type of biomass – pharmaceutical cocktail” configuration 345 
and were represented according to the COD concentration plotted to the amount of TSS 346 
(Figure 4).  347 
On Figure 4, positive and negative velocities respectively show COD degradation and an 348 
inhibitory effect exerted by pharmaceuticals. Non-acclimated WWTP sludge (Rousset, 349 
France) proved to be totally impacted by the presence of pharmaceutical cocktails: 350 
degradation velocity of the COD was zero at low concentrations and even became 351 
negative for high charges. A negative degradation velocity means that the presence of 352 
pharmaceuticals triggered cell lysis of activated sludge. Conversely, positive COD 353 
degradation velocities were measured for sludge acclimated to OWW, which means that 354 
it retains a capacity for purification in the presence of pharmaceuticals. However, COD 355 
degradation velocities were slower than that of the control group without 356 
pharmaceuticals, indicating that pharmaceutical cocktails still partially inhibit the 357 
performance of the biomass, which would be logical given the high concentrations used 358 
in the cocktail. Optimal degradation velocity was around 0.2 gCOD.gTSS-1 for the 359 
acclimated sludge. An inhibition of COD degradation by pharmaceutical materials was 360 
observed from 0.1 gCOD.gTSS-1 for the sludge in sole presence of the antineoplastic 361 
cocktail and from 0.2 gCOD.gTSS-1 for the antineoplastic cocktail with antibiotics. Thus 362 
inhibition seems stronger for the antineoplastic cocktail on its own than for the 363 
combination of antineoplastic and antibiotic cocktails. This surprising observation could 364 
be due to (i) interactions between antineoplastics and antibiotics, which brought about a 365 
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decrease in total pharmaceutical toxicity, or (ii) to the absence of toxicity of the 366 
antibiotics cocktails on acclimated sludge, hence the differences observed in specific 367 
removal velocities of the COD would be due only to experimental uncertainties (COD 368 
measurement precision). A contrasting behavior was observed for the municipal WWTP 369 
sludge. The antineoplastic cocktail in the presence of antibiotics triggered a more 370 
pronounced cell lysis than the sole antineoplastic cocktail, showing that antibiotics have 371 
a bactericidal effect on non-acclimated activated sludge. Thus the acclimated biomass 372 
acquired resistance to the tested antibiotics and may have been able to metabolize them 373 
partially. These results clearly demonstrate that biomass acclimation allowed for the 374 
development of capacities of high resistance to antineoplastics and antibiotics, since, at 375 
low charge, the sludge developed in the hospital MBR was only slightly affected by their 376 
presence.  377 
 378 
III.2. Removal mechanisms of the selected pharmaceuticals 379 
III.2.1 Sorption 380 
Degradation tests in a batch reactor were performed so as to determine the influence of 381 
each of the two removal mechanisms coupled with the purifying biomass: sorption and 382 
biotransformation. These tests must show whether the apparent removal with sludge 383 
acclimated to OWW is mainly linked to a pollutant transfer from the liquid to the solid 384 
phase, or whether there is a biological metabolization by bacteria from the purifying 385 
biomass. Lastly, these tests were also carried out using municipal WWTP activated 386 
sludge from Rousset, so as to quantify the improvement brought by acclimation of 387 
sludge to OWW. 388 
Sorption of the selected pharmaceuticals seemed relatively low for the antineoplastics 389 
molecules on the activated sludge of the sMBRe hospital pilot and for the municipal 390 
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WWTP, as it turned out to be lower than 10% (Figure 5a). Although its sorption 391 
remained very low, ifosfamide seems to have more affinities with sorption than 392 
cyclophosphamide, which is coherent with Seira’s results (2013). Sulfamethazole was 393 
removed a few percent more than antineoplastics for both types of sludge, but its 394 
sorption remained limited as its removal reached a maximum 13% for sludge acclimated 395 
to OWW. Codeine seems to have much more pronounced sorption affinities, since its 396 
removal through sorption reached up to 30% for WWTP sludge. Whichever sludge was 397 
used, the proportion of sorption of pharmaceuticals tended to decrease as its initial 398 
concentration increased, because of a constant number of sorption sites on bacterial 399 
flocs for a larger amount of pollutant.  400 
Thus apparent removal of cyclophosphamide, ifosfamide and sulfamethazole by 401 
acclimated sludge may be attributed to biotransformation.  402 
Although transfer of pollutant from the liquid phase to sludge appears limited, the very 403 
high concentrations in pharmaceuticals in OWW may include significant amounts of 404 
pharmaceuticals sorbed onto the sludge of an MBR treating these OWW. These amounts, 405 
calculated from average concentrations measured in OWW and from corresponding 406 
concentration factors, show that ifosfamide and sulfamethazole might be present in high 407 
concentrations in MBR sludge and should be taken into account when choosing the 408 
appropriate treatment method for excess sludge (Table 3).  409 
The evolution of distribution coefficients KD according to the concentration factor is 410 
logically identical to that of reduction through sorption (Figure 5b). The selected 411 
pharmaceuticals have low distribution coefficients KD. KD was smaller than 40 L.kgTSS-1 412 
for CP, IF and SM and smaller than 120 L.kgTSS-1 for CD in municipal WWTP. Joss et al. 413 
(2005) claimed that for a value of KD smaller than 300 L.kgTSS-1 sorption of a compound 414 
is negligible and its removal may be assessed using input and output concentrations. 415 
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According to Ternes et al. (2004) sorption may be considered as a significant removal 416 
mechanism at a threshold value of 500 L.kgTSS-1. Even though this seems justified for 417 
both antineoplastics, SM sorption represents more than 10% of removal for acclimated 418 
sludge, and more importantly, sorption of CD allows for a removal above 30%. These 419 
observations match Seira’s (2013), who noted that low values of KD could not be 420 
systematically neglected since sometimes significant removal could occur even for 421 
molecules presenting low KD. He proposed to highlight the particle concentrations 422 
associated to any suggestion of KD limit value from which sorption may be considered 423 
negligible. 424 
Sorption of CP, IF and SM proved to be in the same order of magnitude for both tested 425 
activated sludge. The nature of the sludge could have significantly influenced the 426 
sorption affinities of a compound, but comparison between the sludge acclimated to 427 
OWW and that of the Rousset WWTP provided no evidence of this. This was probably 428 
due to the fact that the MBR of the WWTP and that of the MBR which was used for 429 
acclimation had the same configuration (submerged external membrane bioreactor). 430 
Another factor could be the origin of the sludge which was used as a base for 431 
acclimation, which came from the Rousset WWTP. Comparing several studies would be 432 
difficult because of differences in experimental procedures and in the nature of the 433 
sludge (Table 4). 434 
KD coefficients of both antineoplastics (CP and IF) found in the literature are generally 435 
low (Seira, 2013 ; Ternes et al., 2004). High values of KD for CP of 794.3 L.kgTSS-1 436 
(Delgado, 2009) and of 111.4 L.kgTSS-1 (Zaviska, 2013) could be due to the thermic 437 
inhibition technique used, which completely breaks down the biomass (Hamon et al., 438 
2014). For activated sludge from an MBR pilot, Seira (2013) obtained similar results to 439 
those of this study, with a KD of 15 L.kgTSS-1 for CP and of 22 L.kgTSS-1 for IF. It should 440 
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be noted that Seira’s study measured the most pronounced sorption of CP and IF for 441 
eMBR sludge. This was attributed to the smaller-sized flocs, which provided more 442 
sorption sites to compounds. KD coefficients of SM found in the literature seem very 443 
heterogeneous as they range from 3.2 to 370 L.kgTSS-1. These differences could be 444 
explained by the nature of the activated sludge and by the inhibition techniques that 445 
were used, but also by SM photosensitivity (Hörsing et al., 2011), which is negligible in 446 
this study since sorption tests were carried out in brown glass vials. Average values of 447 
34.1 L.kgTSS-1 measured in this study for sludge acclimated to OWW and of 21.4 448 
L.kgTSS-1 for Rousset WWTP sludge were in the same order of magnitude as KD 449 
measured in the studies of Abbeglen (2009) for MBR sludge and Yang et al. (2011) for 450 
conventional WWTP sludge. Significant differences were observed for values of KD 451 
obtained for CD. Again, these differences could be due to the inhibition techniques that 452 
were used and/or to the nature of the activated sludge. It should also be noted that the 453 
sorption assessed in this study is competitive as pharmaceuticals were added as a 454 
cocktail, while the results of some studies in the literature are sorption values of isolated 455 
compounds.  456 
Although sorption of the selected pharmaceuticals may not be totally ignored, it proved 457 
to be a minor removal mechanism for acclimated sludge, except for codeine, which could 458 
be removed through sorption in proportions ranging around 30%. 459 
 460 
III.2.2. Biotransformation 461 
Concerning biotransformation tests, a definite improvement in the total removal of the 4 462 
pharmaceuticals was observed with sludge acclimated to OWW (Figure 6). The initial 463 
concentration was analysed. Except for codeine, which was always removed very 464 
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efficiently whatever the concentration factor, total removal of pharmaceuticals with 465 
acclimated sludge seemed to increase with their initial concentration. Conversely and 466 
except for ifosfamide, removal with sludge from the municipal WWTP seemed to 467 
stagnate when initial concentration increased. Capacities for biotransformation were 468 
developed by sludge acclimated to OWW while removal of selected pharmaceuticals 469 
from the Rousset municipal WWTP sludge was mainly due to a sorption mechanism, as 470 
the following ratio shows:  471 
 472 
-./0123/10./
4/150./  smaller than 1 (Table 5). 473 
 474 
In accordance with literature, the biotransformation measured for the 2 antineoplastics 475 
CP and IF by municipal WWTP sludge proved to be low, even zero (Kümmerer et al., 476 
1997; Buerge et al., 2006). Removal of CD and SM through biotransformation in the 477 
Rousset WWTP sludge was low, as it was in the order of 8% in 4 h. Total removal after 4 478 
h seems to confirm partial removal of these two pharmaceuticals, as mentioned in the 479 
literature. The stagnation of removal which was observed for the municipal WWTP 480 
sludge could show the inhibition effect exerted by the most concentrated 481 
pharmaceutical cocktails. Besides, the 1000 µg.L-1 cocktail of each of these 482 
pharmaceuticals seemed to trigger a very strong inhibition, as a significant decrease in 483 
the reduction of CD was noted. Thus increase in the removal of CP and IF for the most 484 
concentrated cocktail could be due to the sorption of these molecules onto soluble 485 
microbial products which were released during a possible cell lysis brought about by the 486 
pharmaceutical cocktails in the non-acclimated municipal WWTP sludge. The IANESCO 487 
Laboratory is certified and these conclusions are validated by the results of analyses. 488 
These batch reactor tests confirm the correct reductions with 43% maximum removal 489 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
for SM and around 70% for CD in only 4 h (Figure 6). These results agree with those 490 
measured in the supernatant of the MBR during the acclimation period of the sludge. 491 
However, maximum removal of CP at 36% and of IF at 38% in that reduced time scale 492 
seems better than the removal obtained in the MBR. This could stem from the nature of 493 
the substrate, which was far less rich and complex than real OWW, and from the initial 494 
absence of these molecules in the supernatant, which was not the case in the MBR. It 495 
should also be noted that exclusively aerobic conditions (applied in batch reactors) are 496 
known to favor degradation of micropollutants as opposed to aerobic/anoxic processes 497 
(applied in the MBR) (Suarez et al., 2010), even if a 4 h test remains far shorter than the 498 
HRT of the MBR. Although these removals are incomplete, it should be noted that the 499 
differences in the associated concentrations are substantial since they are in the order of 500 
700 µg.L-1 for CD and 400 µg.L-1 for SM, CP and IF. 501 
These removals were obtained without adding a cosubstrate in the batch reactors. Thus 502 
actual biotransformation of the selected pharmaceuticals could be achieved through a 503 
direct metabolic pathway. Seira (2013) did not observe any biotransformation of CP and 504 
IF without adding a cosubstrate, but the concentrations tested in his study, respectively 505 
6 and 2 µg.L-1, were much lower than those of the present study (100 to 1,000 µg.L-1). 506 
The higher concentrations used here are representative of the concentrations measured 507 
in OWW. Such concentrations could allow pharmaceuticals to be used as primary 508 
substrate for the biomass. The data obtained in this study permits to calculate kinetic 509 
parameters for removal by both types of tested activated sludge (Eq.2) for each 510 
pharmaceutical. 511 
 512 
67819:;0.9<
60 = =></?< ∙ @ℎ	

..0.<
  Eq.2 513 
 514 
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kglobal, which is the kinetic constant of total removal measured during the 4h test (µg1-515 
n.Ln-1.h-1), and n, which is the order of the reaction, were then determined through 516 
linearization (Eq.3) :  517 
 518 
log*D 67819:;0.9<60 = log*D =></?< + F ∙ log*D@ℎ	

..0.<  Eq.3 519 
 520 
Representing this equation allows for the determination of the kinetics constant kglobal 521 
(Table 6).  522 
It appears that some degradation kinetics deviate from pseudo-first order, such as that 523 
of cyclophosphamide by acclimated sludge. This deviation may be attributed to 524 
experimental uncertainties or to inhibition by the pharmaceutical cocktail at the highest 525 
concentrations. However, it seems obvious that the order greater than 2 for IF obtained 526 
with the Rousset WWTP sludge is due to the WWTP sludge’s inability to biotransformate 527 
that compound. It is not possible to use a mathematical model for IF. The traditional 528 
model of pseudo-first order was not used and the values of the kinetic constants were 529 
not compared to literature data because their units depend on the order of the reaction. 530 
The biotransformation kinetic constant kbiol and the associated order of the reaction n 531 
may be determined from concentrations at sorption equilibrium [Pharmaceutical]eq and 532 
final [Pharmaceutical]f during the total removal test (Eq.4 and Table 6):  533 
 534 
log*D
7819:;0.9<!G'7819:;0.9<H
0H+0$
= log*D =?./< + F ∙ log*D@ℎ	

..0.< Eq.4 535 
 536 
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After integrating equation 2, previously determined kinetic constants and orders of 537 
reaction allow for the calculation of the residual concentration of pharmaceuticals 538 
according to time (Eq.5):  539 
 540 
@ℎ	

() = K= ∙  ∙ (F − 1) + @ℎ	

	..0.<
(*+) M
N
N'O
 Eq.5 541 
 542 
Thus it is possible to represent a removal profile for each pharmaceutical for both types 543 
of activated sludge. A profile is proposed with the kglobal constant representing maximum 544 
removal of a pharmaceutical, when biotransformation does not limit sorption kinetics 545 
and allows for the release of sorption sites onto bacterial flocs. Another profile is 546 
represented with the kglobal constant for the first 4 hours, then with only kbiol, which 547 
would be the most unfavorable case, i.e. sorption which does not repeat because of very 548 
low biotransformation, which does not allow for the rapid release of sites onto bacterial 549 
flocs.  550 
Final concentration in pharmaceuticals was calculated using Eq.6 up to 4 h then Eq.7 551 
from 4 h respectively, for the profile, which only takes into account the 552 
biotransformation mechanism after 4 h.  553 
From 0 to 4 h: 554 
@ℎ	

() = K=></?< ∙  ∙ (F − 1) + @ℎ	

..0.<
(*+) M
N
N'O
  Eq.6 555 
 556 
Then with t > 4 h: 557 
@ℎ	

() = K=?./< ∙ ( − 4) ∙ (F − 1) + @ℎ	

Q	8
(*+)M
N
N'O
 Eq.7 558 
 559 
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Removal profiles were calculated using the average concentrations of the selected 560 
pharmaceuticals measured in the OWW: 26 – 290 – 1664 - 422 µg.L-1 for codeine (CD) – 561 
Cyclophosphamide (CP) – Isofofammide (IF) – Sulfamethoxazole (SM respectively). The 562 
temporary absence of a molecule in OWW was not taken into account in the calculation 563 
of the average concentration. The evolution of the removal of the 4 pharmaceuticals 564 
from the liquid phase was represented for both types of sludge (Figure 7). It should be 565 
specified that most of the profiles using kglobal overestimated the removal kinetics of the 566 
liquid phase, particularly for the sludge from the Rousset WWTP, as the renewal of 567 
sorption sites depends on the biotransformation mechanism. Hence a low 568 
biotransformation will limit the sorption kinetics once sorption equilibrium has been 569 
attained.  570 
Removal of a pharmaceutical from the liquid phase in a batch reactor is situated 571 
between the two curves which were calculated from kglobal and kbiol. So the actual 572 
evolution of removal of CD, CP and IF for the Rousset WWTP sludge should follow the 573 
curve for removal through biotransformation, as this mechanism limits sorption 574 
kinetics. This kinetics is probably close to the kglobal curve for sludge acclimated to OWW, 575 
because of the developed biotransformation which is greater than sorption, and close to 576 
kbiol for the sludge from the Rousset municipal WWTP. They are the solid lines in Figure 577 
7.  578 
These profiles show the extent of the capacity for biotransformation developed by 579 
activated sludge thanks to on-site treatment of OWW. It seems that SM is the 580 
pharmaceutical which presents the smallest number of differences between the two 581 
types of sludge. The clearest gain from treatment with activated sludge is for the two 582 
antineoplastics (CO and IF), as developed biotransformation enabled us to obtain 583 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
 
significant removals. Moreover, it is logical to suppose that the profile that best 584 
represents removal of antineoplastics for the Rousset WWTP is the profile which only 585 
takes into account biotransformation after 4 h, as sorption does not limit the 586 
biotransformation mechanism, which proved to be quasi null. Obviously all the removal 587 
profiles calculated with the kglobal constant are above the associated profile calculated 588 
with the kbiol constant, except ifosfamide for acclimated sludge, whose two profiles are 589 
practically superposed. This superposing clearly shows that sorption is renewed as the 590 
biotransformation process of IF takes place. Consequently it is possible to determine the 591 
time needed to reach a given reduction. The time needed to obtain a 95% reduction was 592 
determined for both types of sludge (Table 7). 593 
These results clearly demonstrate the gain from the acclimation in an MBR of sludge 594 
acclimated to OWW. However, these durations remain far longer than the average HRT 595 
of the sMBRe pilot used for the 29 h acclimation during the experiment. The removals 596 
that correspond to this average HRT are presented in Table 8.  597 
This calculated data should be interpreted with caution. Comparing removal kinetics of a 598 
batch reactor and of a continuous process may prove delicate, especially as retention of 599 
pharmaceuticals by the membrane, as was observed in this study (Hamon, 2013), 600 
strongly limits that comparison. This data, calculated from kinetic parameters, would 601 
show an excellent removal of IF for acclimated sludge. Still, the performance of the 602 
hospital MBR pilot which was used for acclimation proved to be consistently lower. 603 
These differences may be attributed to the pharmaceutical cocktail created for the tests 604 
in a batch reactor. This cocktail only contained 4 pharmaceuticals, which is far from the 605 
great complexity of OWW as to quantity and quality, without even mentioning 606 
metabolites. Thus the profile of IF removal by sludge acclimated to OWW may be 607 
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questioned for the reasons mentioned above, because of experimental mistakes, or 608 
because of the low experimental concentrations used in IF, compared to OWW 609 
concentrations, which would only trigger an inhibitory effect restricted to the biomass. 610 
Removal of CP at average HRT seems more reliable as the 46% removal calculated from 611 
kbiol is relatively close to reduction in the MBR during acclimation. It should be noted 612 
that subtracting the average sorption part of 3.7% (previously observed for the 613 
activated sludge of the hospital sMBRe pilot) from the 46% removal of CP would give a 614 
biotransformation part of 42.3%. This biotransformed fraction of 42.3% is in the same 615 
order of magnitude as the biotransformation measured by Seira (2013) of 39 ± 5 % in an 616 
eMBR pilot treating urban wastewater with a CP dopant. The developed model also 617 
seems reliable for SM, as its average removal by the MBR during acclimation (75%) was 618 
between the calculated maximum removal and removal through biotransformation. 619 
Lack of data about the sorption of codeine on sludge acclimated to OWW makes it 620 
impossible to conclude on the validity of the model for that pharmaceutical.  621 
 622 
IV. Conclusion 623 
Removal of the selected pharmaceutical molecules by activated sludge acclimated to 624 
OWW and non-acclimated sludge from the municipal WWTP confirms literature 625 
observations on the heterogeneity of the removal of pharmaceuticals. 5-FU was almost 626 
systematically removed beyond 90%. This molecule is easily removable, as the 627 
performance of WWTP sludge confirmed. It is important to specify that (i) even if 628 
removal of 5-FU by sludge acclimated to OWW seems identical to that by WWTP sludge, 629 
sludge acclimation was obtained in the presence of other inhibitory compounds 630 
contained in the effluents of the oncological ward (pharmaceuticals, surface-active 631 
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agents), which makes the results all the more remarkable, and (ii) using sludge 632 
acclimated to OWW allowed for a 34% increase in the degradation kinetic constant and 633 
in the minimum inhibition concentration.  634 
Acclimation of activated sludge to OWW in an MBR brought about the creation of 635 
extensive capacity for biotransformation and the acquisition of a very pronounced 636 
resistance to the most widely consumed antibiotics in the oncological ward. While 637 
sorption is the main, or even the only, removal mechanism by non-acclimated WWTP 638 
sludge, treatment by acclimated sludge provides a significant improvement in the 639 
removal of the selected pharmaceuticals. Hence 20% of the amounts of CP, IF and SM 640 
can be removed by biotransformation in a mere 4 h. With the exception of codeine for 641 
which sorption reaches 30%, sorption of the selected pharmaceuticals onto sludge 642 
proved minor, as it was lower than or in the order of 10% for both types of tested 643 
sludge. If removal by sorption is low, adsorbed quantities still remain significant, 644 
because of the high concentrations in pharmaceuticals of hospital effluents, and more 645 
specifically effluents from a care unit. Thus pollutant transfer from the liquid to the solid 646 
phase must be taken into account when determining the suitable process for the 647 
treatment of sludge.  648 
These results are positive, as they show that the observed removal of pharmaceutical 649 
molecules by an acclimated biomass can mostly be attributed to developed 650 
biotransformation, in comparison with the sorption phenomenon. The acclimated 651 
activated sludge showed a great capacity for adaptation to the pharmaceuticals 652 
contained in the OWW. That observation is supported by the conservation of the 653 
purifying capacities of the biomass in the presence of a pharmaceutical cocktail, the 654 
acquisition of a pronounced resistance to antibiotics and, most of all, by the creation of 655 
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biotransformation capacities on the selected pharmaceuticals. A systematic 656 
improvement of the performance of the acclimated activated sludge, compared to that of 657 
activated WWTP sludge, was obtained in spite of the presence of numerous compounds 658 
(pharmaceuticals, metabolites, and cleaning products) in the OWW. These compounds 659 
sometimes inhibited the development of the biomass and its purifying performance on 660 
the COD, ammonium and nitrates during acclimation. Furthermore, it has to be noted 661 
that the development of a pronounced resistance to antibiotics must be seriously 662 
studied with regard to human health and the environment in order to validate the 663 
biological treatment at the source of highly concentrated antibiotics effluent. 664 
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List of symbols 
5-FU Fluorouracile 
OWW oncological ward wastewater 
WWTP wastewater treatment plant 
eMBR external membrane bioreactor 
sMBRe 
external submerged membrane 
bioreactor 
TSS Total Suspended Solids (g.L
-1)
 
COD chemical oxygen demand (mgO2.L
-1
) 
CP cyclophosphamide 
IF ifosfamide 
SM sulfamethoxazole 
CD codeine 
CF concentration factor 
SRT sludge retention time 
HRT hydraulic retention time (h) 
 671 
 672 
 
kbiol Biotransformation kinetic constant L.gTSS
-1
.d
-1
 
KD Solid-water distribution coefficient L.kgTSS
-1
 
kglobal Maximum removal constant µg
1-n
.L
n-1
.d
-1
 
[5-
FU]max  
5-FU maximum concentration detected in OWW µg.L
-1
 
nmed Yearly amount of pharmaceutical molecule consumed in the 
oncological ward 
mg.year
-1
 
n5-FU  Yearly amount of 5-FU consumed in the oncological ward mg.year
-1
 
1-τmed  Rate of unmetabolized pharmaceutical - 
1-τ5-FU  Rate of unmetabolized 5-FU - 
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Figure 1. Specific removal velocity of 5-FU in eMBR treating OWW.  32 
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Figure 2. 5-FU removal in batch reactor for activated sludge from municipal WWTP and activated sludge from the eMBR 35 
treating OWW. 36 
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Figure 3. Evolution of kbiol for activated sludge from municipal WWTP and eMBR treating OWW. 40 
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Figure 4. COD specific removal velocity in presence of pharmaceuticals for activated sludge from municipal WWTP and 43 
the eMBR treating OWW. 44 
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Figure 5. Removal of the selected pharmaceuticals due to sorption (a) and values of KD for the selected 52 
pharmaceuticals (b) for both activated sludge from municipal WWTP and the sMBRe treating OWW.  53 
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55 
 56 
Figure 6. 4hours removal of the selected pharmaceuticals for both activated sludge from municipal WWTP 57 
and the sMBRe treating OWW. 58 
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 61 
Figure 7. Removal evolution of the 4 selected pharmaceuticals by both activated sludge. 62 
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 64 
 65 
Table 1: State and performance of activated sludge at the sampling date 66 
 M
B
R
 c
h
a
ra
ct
e
ri
st
ic
s 
Supplier CTI Polymem 
Type Carbosep® M1 M2 
Configuration Tubular-monocanal 
Frontal extern-intern / 260 
hollow fibers 
Material ZrO2-TiO2 Polysulfone 
Initial permeability  
(L.h-1.m-2.bar-1) 
110 130 
Molecular weight cut-off 
(kDa) 
150 100 
Total filtration surface (m²) 0.0222 0.4 
Length (m) 1.20 0.6 
Internal diameter/external 
diameter (mm) 
06 / 10 0.85 / 1.44 
    min max average min max average 
O
p
e
ra
ti
n
g
 c
o
n
d
it
io
n
s 
Permeate flow rate (L.h-1) 1 2 1.42 ± 0.22 0.8 2 1.13 ± 0.27 
Hydraulic retention time (h) 16 32 23.0 ± 3.6 16 40 29 ± 8 
Transmembrane pressure 
(bar) 
0.8 2.2 1.30 ± 0.23 0.06 0.75 0.39 ± 0.18 
Sludge retention time Infinite Infinite 
Cycle aerated / not aerated 
(h) 
2 / 1 2 / 1 
O
p
e
ra
ti
n
g
 c
o
n
d
it
io
n
s 
a
t 
th
e
 
sa
m
p
lin
g
 t
im
e
 
Acclimation to OWW duration 
(d) 
160 180 
TSS (g.L-1) 4.0 4.1 
Biomass evolution growth stabilisation 
CODS removal (%) 94 35 
CODP removal (%) 98 89 
N-NH4
+ removal (%) 99 100 
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Table 2: Concentrations of the antineoplastic and antibiotic cocktail 69 
 70 
  71 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
 72 
Table 3: Quantity of sorbed pharmaceutical onto activated sludge. 73 
Molecule 
OWWaverage 
(µg.L
-1
) 
Corresponding 
CF  
Corresponding 
removal efficiency 
(%) 
Specific quantity of sorbed 
pharmaceutical (µg.gTSS
-1
) 
CD 26 1 31.3 (WWTP) 2 
CP 290 2.5 4.3 3 
IF 1664 10 2.7 11 
SM 422 5 12.3 13 
 74 
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 76 
Table 4. KD values of selected pharmaceuticals reported in previous studies. 77 
Molecule KD (L.kgTSS
-1
) Activated sludge origin  Inhibition technique Reference 
CD 
- sMBRe – infinite SRT Anaerobic Present study 
102.1 ± 8.9 sMBRe WWTP Anaerobic Present study 
Sorption too low to 
be quantified 
primary - secondary at weak SRT – 
secondary at long SRT 
AS are slightly frozen then 
sterilized at 103°C during 3h 
Hörsing et al., 2011 
14 ± 1 Conventional WWTP Sodium azide 0.2 % (v/v) Wick et al., 2009 
CP 
9.6 ± 3.8 sMBRe – infinite SRT Anaerobic Present study 
17.7 ± 4.0 sMBRe WWTP Anaerobic Present study 
15 - 12 - 0 –  
47 - 20 - 32 
eMBR - Conventional WWTP – Sludge 
thickener - Conventional WWTP – 
sMBRe - Conventional WWTP 
Gas purging Seira (2013) 
794.28 eMBR Thermal Delgado (2009) 
2.4 ± 0.5 WWTP Gas purging Ternes et al., 2004 
log KD about 3.2 --> 
KD = 1600 
Primary sludge - Okuda et al., 2009 
IF 
17.1 ± 2.1 sMBRe – infinite SRT Anaerobic Present study 
15.9 ± 0.6 sMBRe WWTP Anaerobic Present study 
22-71-7-87-55-63 
eMBR - Conventional WWTP – Sludge 
thickener - Conventional WWTP – 
sMBRe - Conventional WWTP  
Gas purging Seira (2013) 
1.4 ± 0.4 WWTP Gas purging Ternes et al., 2004 
SM 
34.1 ± 7.3 sMBRe – infinite SRT Anaerobic Present study 
21.4 ± 2.0 sMBRe WWTP Anaerobic Present study 
256 ± 169 Conventional WWTP Freeze-drying Göbel et al., 2005 
3.2 ± 4.5 - 77 ± 60 - 
60 ± 49 - 63 ± 42 
Primary sludge – Secondary sludge – 
MBR flat sheets – MBR hollow fibers 
Freeze-drying Radjenovic et al., 2009 
40 ± 13 - 50 ± 13 MBR - Abbeglen et al., 2009 
320 - 370 - 280 
primary - secondary at weak SRT – 
secondary at long SRT 
AS are slightly frozen then 
sterilized at 103°C during 3h 
Hörsing et al., 2011 
<30 
Primary and two different secondary 
activated sludge 
Lyophilization and dry-heat Stevens-Garmon et al., 2011 
28.6 ± 1.9 Conventional WWTP Sodium azide 1 g.L
-1
 Yang et al., 2011 
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Table 5. 4 hours removal of the selected pharmaceuticals by both activated sludge.
*
 80 
Molecule 
sMBRe – acclimated to OWW sMBRe municipal WWTP 
Total (%) 
Biotrans 
formation (%) 
Sorption 
(%) 
	


 Total (%) 
Biotrans 
formation (%) 
Sorption 
(%) 
	


 
CD 66.1 ± 5.1 - - - 36.6 ± 6.3 7.9 28.7 ± 3.8 0.3 
CP 
21.9 ± 
10.1 
18.2 3.7 ± 1.4 4.9 9.7 ± 2.8 3.1 6.6 ± 1.4 
0.5 
IF 26.8 ± 7.9 20.5 6.3 ± 2.5 3.2 5.2 ± 5.6 -0.7 5.9 ± 2.1 Solely sorption 
SM 31.3 ± 9.4 19.4 11.9 ± 1.8 1.6 16.2 ± 2.7 8.4 7.8 ± 1.5 1.1 
*Values presented relate the average removals calculated from the 4 concentration factors.  81 
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Table 6. k and n values for the total and biotransformation removal by both activated sludge. 83 
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Table 7. Required duration to achieve 95 % removal of the selected pharmaceuticals for both activated 85 
sludge. 86 
Molecule 
sMBRe/OWW  
sMBRe/municipal 
WWTP sMBRe/OWW 
sMBRe/municipal 
WWTP 
t95% max (h) t95% bio (h) t95% max (h) t95% bio (h) 
Codeine (CD) 16 22 - 94 
Cyclophosphamide (CP) 170 212 408 4849 
Ifosfamide (IF) 44 619 61 Never 
Sulfamethoxazole (SM) 57 86 150 336 
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Table 8. Removals of the selected pharmaceuticals for both activated sludge at the average HRT of 29h of the 89 
sMBRe pilot treating OWW. 90 
Molecule 
sMBRe/OWW sMBRe/municipal WWTP 
Max removal 
(%) 
Bio removal 
 (%) 
Max removal 
(%) 
Bio removal 
 (%) 
Codeine (CD) 99.6 - 98.6 67.0 
Cyclophosphamide (CP) 58.8 46.0 42.9 13.7 
Ifosfamide (IF) 88.6 91.8 71.5 34.0 
Sulfamethoxazole (SM) 84.3 69.3 68.1 46.6 
 91 
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 (i) Acclimated sludge allowed for a 34% increase in the degradation kinetic constant 
(ii) Acclimated sludge allowed an increase in the minimum inhibition concentration. 
(iii) Sorption of pharmaceuticals onto sludge proved minor in comparison of biosorption 
(iv) Removal of pharmaceuticals is attributed to developed biotransformation  
(v) High removal factor for 5-FU whatever the presence of other inhibitory compounds 
